NCT Number: NCT02414412
Immunity Improvement Effect of Ulmus Macrocarpa Water Extract in Adults
This randomized, placebo-controlled, double-blind study evaluates the efficacy and tolerability of Ulmus macrocarpa water extract for immunity improvement in relatively healthy adults. 58 subjects received 500 mg of Ulmus macrocarpa water extract per day or a placebo for 4 weeks.
Looking for future studies?
Notify MeKey information
Conditions
Age range
19 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- subject has peripheral white blood cells between 4,000/Ul and 8,000/Ul
Exclusion criteria
- History of renal disease
- History of diabetes mellitus
- History of immune disease
Treatment and study plan
Primary outcomes
-
serum natural killer cell activity
Time frame: 1 month
Secondary outcomes
-
peripheral white blood cell
Time frame: 1 month
-
serum tumor necrosis factor-alpha level
Time frame: 1 month
-
serum interferon-gamma
Time frame: 1 month
-
serum interleukins(1betta, 2,4,8,10, and 12)
Time frame: 1 month
Sponsors and collaborators
Lead sponsor
Pusan National University Hospital
Other
Collaborators
- Bio Port Korea Inc.
Registry information
Important dates
- Study start
- 2015
- Primary completion
- 2015
- Study completion
- 2015
- First posted
- Apr 10, 2015
- Registry last updated
- Nov 3, 2015
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Tumor-Derived FGF19
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsAI Chatbot for HPV Vaccine Literacy Among Caregivers in Japan
NCT06702423
Healthy
London, United Kingdom
View Trial DetailsValidation of the Masimo Irregular Heartbeat Detection Algorithm in Participants Without Cardiovascular Disease
NCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNormative Value for Navicular Drop Test in Older Adults
NCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details